AlphaDetect is accelerating the detection of Alpha-1 Antitrypsin Deficiency (Alpha-1), so everyone at risk of this genetic condition is identified and informed earlier. Powered by the Alpha-1 Foundation (A1F), we’re unifying the community to expand reach, remove barriers, and make genetic testing for Alpha-1 more routine among those impacted by lung and liver disease. Follow us. Share our posts. Together, we can ensure that people with Alpha-1, and those who care for them, receive the timely answers they need for critical decision-making. Founded in 2025, AlphaDetect operates as a limited liability company and wholly owned non-profit charitable subsidiary of A1F, deriving tax-exempt status under Section 501(c)(3) of the Internal Revenue Code.